Abstract:Background: Differences in lung function for Chronic Obstructive Pulmonary Disease (COPD) cause bias in the findings when identifying frequent exacerbator phenotype-related causes. The aim of this study was to determine whether computed tomographic (CT) biomarkers and circulating inflammatory biomarkers were associated with the COPD frequent exacerbator phenotype after eliminating the differences in lung function between a frequent exacerbator (FE) group and a non-frequent exacerbator (NFE) group. Methods: A total of 212 patients with stable COPD were divided into a FE group (n=106) and a NFE group (n=106) according to their exacerbation history. These patients were assessed by spirometry, quantitative CT measurements and blood sample measurements during their stable phase. Univariate and multivariate logistic regression were used to assess the association between airway thickening or serum cytokines and the COPD frequent exacerbator phenotype. Receiver operating characteristic (ROC) curves were calculated for Pi10, WA%, IL-1β and IL-4 to identify frequent exacerbators. Results: Compared with NFE group, FE group had a greater inner perimeter wall thickness of a 10 mm diameter bronchiole (Pi10), a greater airway wall area percentage (WA%) and higher concentrations of IL-1β and IL-4 (p<0.001). After adjusting for sex, age, BMI, FEV1%pred and smoking pack-years, Pi10, WA%, IL-β and IL-4 were independently associated with a frequent exacerbator phenotype (p<0.001). Additionally, there was an increase in the odds ratio of the frequent exacerbator phenotype with increasing Pi10, WA%, IL-4, and IL-1β (p for trend <0.001). The ROC curve demonstrated that IL-1β had a significantly larger calculated area under the curve (p < 0.05) than Pi10, WA% and IL-4. Conclusion: Pi10, WA%, IL-4, and IL-1β were independently associated with the frequent exacerbator phenotype among patients with stable COPD, suggesting that chronic airway and systemic inflammation contribute to the frequent exacerbator phenotype. Trial registration: This trial was registered in Chinese Clinical Trial Registry (https://www.chictr.org.cn). Its registration number is ChiCTR2000038700, and date of registration is September 29, 2020.

Clinical analysis of COPD with bronchodilator reversibility in 47 patients

Clinical analysis of COPD cases with positive bronchial dilation test

[A Study of Airway Reactivity and Nature of Chronic Asthmatic Bronchitis].

Bronchodilator reversibility in asthma and COPD: findings from three large population studies

Study on Small Airway Function in COPD Patients with Positive Bronchial Dilation Test

Analysis of influential factors in bronchodilation test in mechanically ventilated patients with chronic obstructive pulmonary diseases

[The Relationship Between Bronchial Hyperresponsiveness and Chronic Obstructive Pulmonary Disease].

Clinical Application of Impulse Oscillation System Determining Bronchodilator Reversibility Test in the Children of Different Ages

The Value of Fractional Exhaled Nitric Oxide and Forced Mid-Expiratory Flow As Predictive Markers of Bronchial Hyperresponsiveness in Adults with Chronic Cough.

The Implication of Biomarkers in Exhaled Breath Condensate of Chronic Obstructive Pulmonary Disease

Clinical Significance of Detection of Inflammatory Markers in Induced Sputumfor COPD Patients with Positive Bronchodilation Test

REDUCED BRONCHODILATOR REVERSIBILITY CORRELATES WITH SEVERE ASTHMA AND MORE EXACERBATIONS: A PROSPECTIVE 12‐MONTH COHORT STUDY IN A REAL‐WORLD SETTING

Assessment of Lung Function during Changes of Chronic Obstructive Pulmonary Disease

Changes of EFL, FEV1 and IC in Patients with Chronice Obstructive Pulomonary Disease and Asthma after Inhaling Bronchodilators

Analysis of Airway Thickening and Serum Cytokines in COPD Patients with Frequent Exacerbations: A Heart of the Matter

Analysis of clinical features of acute exacerbated chronic obstructive pulmonary disease patients

Clinical study of chronic obstructive pulmonary disease combine with bronchiectasis

Analysis of Bronchial Hyper-Reactivity in Patients with Lung Cancer

Diagnostic Value of Various Pulmonary Function Standards of Bronchodilation Test

Residual Volume and Total Lung Capacity to Assess Reversibility in Obstructive Lung Disease

Residual reversibility in COPD patients already on long-acting bronchodilator: The OscilloRevers Study